STOCK TITAN
  1. Home
  2. Sec-filings
  3. BCLI
  4. [8-K] Brainstorm Cell Therapeutics Inc. Reports Material Event

[8-K] Brainstorm Cell Therapeutics Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock BCLI logo
Brainstorm Cell Therapeutics I

OTC:BCLI

BCLI Rankings

#5964 Ranked by Market Cap
N/A Ranked by Dividends

BCLI Latest News

Aug 14, 2025
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 8, 2025
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
Jul 17, 2025
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
Jul 8, 2025
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness
Jun 16, 2025
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

BCLI Latest SEC Filings

Jul 3, 2025
[S-8] Brainstorm Cell Therapeutics Inc. Employee Benefit Plan Registration
Jun 25, 2025
[S-3] Brainstorm Cell Therapeutics Inc. Shelf Registration Statement
Jun 25, 2025
[8-K] Brainstorm Cell Therapeutics Inc. Reports Material Event

BCLI Stock Data

12.00M
9.11M
11.92%
3.79%
6.14%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK